Regulatory
Published · Updated · 1 min read
EMA: furazidine product list contains no clinical data or safety assessment
What it means for practice
The product list alone provides no basis for changing furazidine prescribing. Safety conclusions require a document containing a regulatory assessment or decision.
Summary
The European Medicines Agency (EMA) document “Furazidine: List of nationally authorised medicinal products” concerns medicines containing furazidine that hold national authorisations in various European countries. According to the supplied description, it includes product names, authorisation numbers and details of marketing authorisation holders.
What the source contains
This is an administrative product list, not a report of clinical study results. The supplied description explicitly states that the document contains no clinical data or safety assessments for these medicines. It reports no treatment outcomes, study population characteristics or quantitative risk estimates.
Limits of interpretation
The description does not establish whether a separate decision has been made on changes to product information, restrictions on use or risk minimisation measures for furazidine. Inclusion in the list should not be interpreted as a new conclusion about efficacy or safety. Clinical conclusions require the relevant regulatory assessment or decision document rather than a list of authorised products alone.
Source
-
European Medicines Agency (EMA). Furazidine : List of nationally authorised medicinal products - PSUSA/00011098/202602.
Reviewed by: DrugCard editorial team ·
This article does not replace clinical judgement. Disclaimer
